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Background: A clinical overlap exists between mosaic Neurofibromatosis Type 2 and sporadic Schwannomatosis
conditions. In these cases a molecular analysis of tumors is recommended for a proper genetic diagnostics. This
analysis is challenged by the fact that schwannomas in both conditions bear a somatic double inactivation of the
NF2 gene. However, SMARCB1-associated schwannomas follow a four-hit, three-step model, in which both alleles of
SMARCB1 and NF2 genes are inactivated in the tumor, with one of the steps being always the loss of a big part of
chromosome 22 involving both loci.
Case presentation: Here we report a 36-year-old woman who only presented multiple subcutaneous schwannomas
on her right leg. To help discriminate between both possible diagnoses, an exhaustive molecular genetic and genomic
analysis was performed on two schwannomas of the patient, consisting in cDNA and DNA sequencing, MLPA,
microsatellite multiplex PCR and SNP-array analyses. The loss of a big part of chromosome 22 (22q12.1q13.33)
was identified in both tumors. However, this loss involved the NF2 but not the SMARCB1 locus. SNP-array analysis
revealed the presence of the same deletion breakpoint in both schwannomas, indicating that this alteration was
actually the first NF2 inactivating hit. In addition, a distinct NF2 point mutation in each tumor was identified,
representing independent second hits. In accordance with these results, no deletions or point mutations in the
SMARCB1 gene were identified. None of the mutations were present in the blood. Two of the patient’s children
inherited chromosome 22 deleted in schwannomas of the mother, but in its wild type form.
Conclusions: These results conclusively confirm the segmental mosaic NF2 nature of the clinical phenotype
presented.
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Schwannomas are benign tumours of the nerve sheath
mainly composed by Schwann cells. Solitary schwanno-
mas can appear sporadically in the general population
but when present in multiple form they are associated to
Neurofibromatosis type 2 (NF2) or to Schwannomatosis.
NF2 (MIM 101000) is an autosomal-dominant cancer
syndrome caused by mutations in the NF2 gene, located
on chromosome 22q12.2. NF2 has an incidence of 1 in
33.000 live births, is characterized by the presence of
schwannomas, meningiomas and other tumors, and
distinctively characterized by the presence of bilateral
vestibular schwannomas (VS) with a nearly complete
penetrance at the age of 60 [1]. Over 50% of patients
are familial cases and the remaining are de novo cases.
Schwannomatosis (MIM 162091) is another autosomal-
dominant syndrome characterized by the development of
multiple schwannomas [2]. Schwannomatosis is partially
explained by mutations in the SMARCB1 gene [3], located
6 Mb centromeric to the NF2 gene at 22q11.23. Approxi-
mately 10% of patients with Schwannomatosis have a fam-
ily history, while the remaining 90% have sporadic disease.
About 40-50% of familial Schwannomatosis and less than
10% of sporadic patients have an identifiable SMARCB1
mutation [4-8]. A new gene, LZTR1, located at 22q11.21
and centromeric to SMARCB1 has been recently reported
to be mutated in ~80% of Schwannomatosis patients
negative for SMARCB1 mutation [9].
In the absence of other characteristic NF2 manifesta-
tions, the presence/absence of bilateral VS and intra-
dermal schwannomas are the main clinical criteria to
differentiate Schwannomatosis from NF2 [2,8]. There
is a phenotypic overlap among patients that are mosaic
NF2 and patients with sporadic Schwannomatosis,
consisting of the presence of multiple non-vestibular
nerve schwannomas. The sensitivity of blood genetic
analysis is challenged in these situations [10,11]. The
histological and immunohistochemical characteristics
of schwannomas in Schwannomatosis and NF2 condi-
tions are very similar, with no single robust identifiable
feature serving for diagnostic purposes [2,12]. Thus, in
patients with a phenotypic overlap, the molecular genetic
analysis of the NF2 and SMARCB1 genes in at least two
anatomically distinct tumors has been the recommended
approach to detect the causative mutation [2,13]. The de-
tection of the same mutation in two independent schwan-
nomas, followed by the presence of two distinct second
hits in the other alleles, could be indicative of one of the
two conditions. The molecular analysis can be difficult
when a first hit involves a large region of chromosome 22.
In NF2-related schwannomas, sporadic vestibular schwan-
nomas and Schwannomatosis-related schwannomas, the
NF2 gene is commonly found inactivated in both alleles,
with a high percentage of mutations revealed by loss ofheterozygosity (LOH) [14,15]. However, schwannomas
from SMARCB1 positive patients follow a four-hit,
three-step model of tumorigenesis [4-6] in which both
alleles of SMARCB1 and NF2 genes are inactivated in
the tumor. In addition to the constitutive SMARCB1
mutation, a second step consists in the loss of chromosome
22q, or a segment of it, involving the two loci, followed by a
somatic mutation of the remaining wild-type NF2 allele
that constitutes the third step and the four hit [2]. The
four-hit, three-step model, is also present in schwannomas
from LZTR1 patients, involving LZTR1 and NF2 genes [9].
Different studies describing patient phenotypes charac-
terized by multiple schwannomas restricted to one side or
segment of the body have been reported (e.g. [14,16-18]).
Some of these studies attempted to clarify the diagno-
sis of these patients by genetically characterizing two
or more schwanomas from single patients. Some stud-
ies were not conclusive; others suggested either NF2 or
Schwannomatosis. Most of these studies were performed
before having a clear picture of the four-hit, three-step
model, that SMARCB1 positive patients exhibit in their
schwannomas.
Here we report a woman with multiple schwannomas
confined to one limb. An exhaustive molecular genetic
analysis was performed in two schwannomas of the patient
to identify mutations in the NF2 and SMARCB1 genes, in-
cluding cDNA and DNA sequencing, MLPA, microsatellite




A 36-year-old woman was referred to our NF2 Clinics
because she had developed several tumors limited to the
right leg during the last 6 years. Her family history was
negative for cutaneous tumors or central nervous system
disease. On examination, 2 deep painful tumors confined
to the right calf muscle and two other violet nodules at
the internal malleolus in the same leg, were palpable.
General examination of the skin did not reveal cafe-au-lait
spots, freckling of the axillary region, or other tumors sug-
gestive of neurofibromas. Ophthalmological examination
by split-lamp dismissed the presence of Lisch nodules,
cataract or posterior lens opacities. Audiometric inspec-
tion was normal. Magnetic resonance imaging (MRI)
excluded the presence of vestibular schwannomas (VS),
but identified 5 tumors on the right leg (Figure 1A). The
one located at the right internal malleolus (T1) and the
one at the inside part of the right foot (T2) were surgically
removed and molecularly analyzed (Figure 1B).
Pathological and immunohistochemical features
Biopsy specimens from the two different tumors re-
moved showed an encapsulated spindle cell proliferation
AB
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Figure 1 Tumour location and description. (A) Magnetic resonance image showing all tumors developed in patient’s right leg and picture
details of one of the resected schwannomas. (B) Scheme of the location of the two resected schwanomas. The tumor located at the right
internal malleolus (T1) and the one on the inside of the right foot (T2) were surgically removed and processed to obtain DNA and RNA from
both samples. (C) Immunohistochemical characterization of schwannomas surgically removed. Top image shows that T1 was mainly composed
of large spindle cells with palisaded nuclei and occasional large, hyperchromatic nuclei (degenerative atypia). In the middle image it can be seen
that T1 tumor cells showed intense and diffuse nuclear and cytoplasmic immunoreaction for S100. Bottom image illustrates a SMARCB1 staining
of T1 revealing a mosaic pattern of immunoreactivity.
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(Verocay bodies), and a less frequent loose-textured
component with round nuclei and loose-knit processes
(Antoni B). Focal thick-walled, hyalinized blood vessels,
lymphocytic infiltrate, foamy histiocytes and degenerative
tumoral atypia were also present. Strong and uniform
inmunoreaction for S100 (polyclonal, dilution 1/4000,
DAKO) protein was seen and analysis of SMARCB1 ex-
pression (dilution 1/200 BD Transduction Laboratories)
revealed a mosaic pattern of immunoreactivity, with
patchy loss of protein expression (Figure 1C). In both
cases a schwannoma was diagnosed.
Molecular genetic analysis
Due to the localized presence of schwannomas, a segmen-
tal mosaicism was hypothesized and so the genetic study
was performed first by analyzing the two schwannomas
excised. A microsatellite multiplex PCR (MMP) analysiswas performed using microsatellites scattered within or
around NF2 and SMARCB1 genes and also covering the
chromosome 22q arm, using DNA from both tumors and
comparing it to the blood DNA. This analysis revealed a
loss of heterozygosisty (LOH) from marker D22s929 to
D22s274 in both tumors, involving the NF2 gene but not
SMARCB1 or other centromeric regions (Figure 2A).
Posterior MLPA analysis (data not shown) indicated
the presence of only one copy of the NF2 gene in both
tumors while the two copies of SMARCB1 were
present (P258-B1 and P044-B1 kits, MRC-Holland). To
characterize whether chromosome 22q deletion break-
points were identical or not in both schwannomas,
SNP-array analysis was performed (CytoScan® 750 K,
Affymetrix). Both tumors revealed an identical break-
point localized between C-6CEST (28562441 bp) and
C-5PZZU (28570334 bp) markers (Figure 2A), indicat-
ing this deletion as the first hit event occurred. After
Figure 2 (See legend on next page.)
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Figure 2 Mutational analysis. (A) 1st hit detection: analysis of chromosome 22. (A.1) Chromosome 22 analysis by Multiplex Microsatellite PCR
(MMP) using blood, T1 and T2 gDNA samples. Light blue line: heterozygous region; solid blue line: loss of heterozigosity (LOH); dashed line: LOH
region not determined by MMP but confirmed by MLPA. Location of NF2, SMARCB1 and LZTR1 genes are indicated in green. Microsatellite position is
indicated with a red line (o = no LOH, • = LOH). (A.2) Loss of chromosome 22 and LOH analysis characterized by SNP-array. A two-band pattern in the
allele frequency plot indicates LOH from position 28570333 bp up to the telomere of chromosome 22q. Log2 Ratio < 0 indicates the loss of one copy
of the same region. Breakpoint is indicated by a vertical grey dashed line. (B) Characterization of 2nd hit NF2 mutations in both tumors. Mutations at
DNA and RNA levels are shown. The effect of mutations on splicing alteration is schematically represented. Forward sequence of exon 3 at gDNA level
from T1 (B.1) and exon 14 from T2 (B.2) are shown, accompanied by the effect at mRNA level and an schematic representation. (C) Haplotypes of
patient’s family pedigree and analyzed tumors. MMP markers are indicated in blue. Chromosome 22q loss in tumors is indicated by a red box. Patient’s
daughters inherited chromosome 22 carrying the first hit mutation in patient’s tumors but in its wild-type form.
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genes were sequenced in tumor T1. A homozygous
g.35660 T > C change at the donor site of exon 3
(c.373 + 2 T > C) of NF2 was identified and confirmed
to be the cause of the skipping of exon 3 at mRNA
level (r.254_373del; p. Lys80_Gln121del) (Figure 2B).
No point mutation was identified in the SMARCB1
gene. The NF2 mutation g.35660 T > C found in T1
was not present in T2. In contrast, a new mutation in
the donor site of exon 14 was detected (g.74770G > A;
c.1250 + 1G > A), which caused the insertion of 78 bp
of intron 14 at mRNA level (r.1250_1251insNG_00957.1:
g.74771_074848; p.Val526Asnfs*2) (Figure 2B). Both inde-
pendent mutations were interpreted as independent NF2
second hits. None of these mutations were identified in
blood, indicating the mosaic nature of the disease.
Our patient was 36 years old at the time of genetic
testing and had no VS developed. Although there is risk
for disease transmission of NF2 in mosaic patients [10,11]
the risk level depends on the degree of mosaicism. In seg-
mental mosaic patients the risk of disease transmission is
thought to be low, but not negligible [10,11]. In our case,
the study of the haplotype of the patient’s two children
taken together with the results of the MLPA analysis of
the mother, showed that the two children had inherited
the wildtype form of chromosome 22 that is deleted in the
mother; and are therefore not at risk of developing NF2.
Conclusions
Altogether, these results indicated that the presence of
schwannomas confined to one limb were caused by a
first hit, the loss of one copy of 22q12.1q13.33, involving
the NF2 gene and affecting at least the schwannoma-
initiating cells present in this limb segment, followed by
second hits inactivating the remaining functional copy of
NF2 as an independent event in each schwannoma
developed.
A minimum of 25-33% of NF2 sporadic cases are
mosaic [10], and a few of them develop multiple schwan-
nomas confined to one body segment (see for instance
[14,16-18]). The four-hit, three-step model of tumorigen-
esis of schwannomas from SMARCB1 positive patientsforced us to perform an exhaustive mutational analysis of
both SMARCB1 and NF2 genes, since they are somatically
inactivated in both alleles. The existence of a loss of a
large part of chromosome 22q in both tumors added a
further complication. However, the lack of involvement
of the SMARCB1 gene (neither LZTR1) in the lost
22q12.1q13.33 region, together with the identification
by SNP-array analysis of the same breakpoint in both
schwannomas, pointed to this molecular event as the
first hit occurring in at least the schwannoma-initiating
cells present in this limb segment of the patient. Ac-
cordingly, two independent NF2 mutations, one in each
schwannoma, were identified as second hits. The lack of
any other point mutation or small deletion in the
SMARCB1 gene in either of them, and the lack of any
mutation in the blood, confirmed de NF2 segmental
mosaic nature of this patient’s phenotype.
The results highlight the importance of undertaking a
mutational analysis for NF2 and SMARCB1 in at least 2
schwannomas in sporadic patients with a Schwannoma-
tosis phenotype before concluding a clinical diagnostics.
This analysis is essential in segmental presentations. Re-
cently, a new Schwannomatosis gene, LZTR1, has been
discovered [9]. Schwannomas of LZTR1 positive patients
also follow a three-step four hit model involving LZTR1
and NF2 genes. Thus, in future studies, the molecular
characterization we performed in both schwannomas
will have to take into account the three genes, being
guided by the extension of LOH in chromosome 22q.
The identification of a first event common in all schwan-
nomas studied allowed us to make the pre-symptomatic
genetic diagnostics of the patient’s offspring. This work
can contribute to incorporate genomic tools to the genetic
diagnostic algorithms of hereditary cancers when mosai-
cism is suspected and when the analysis has to be per-
formed preferentially at a somatic level.
Consent
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